Heart Attack

Clinical Trial Finder

Many patients with heart disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Long-term Remote Ischemic Preconditioning Improve Long-term Prognosis of Acute Myocardial Infarction Patients Without Emergency Reperfusion Therapy

Condition:   Myocardial Infarction [C14.280.647.500]
Intervention:   Other: reported remote ischemic preconditioning (RIPC)
Sponsor:   Xuanwu Hospital, Beijing
Not yet recruiting - verified July 2016

Effect and Efficacy of Xpedition™/Alpine™, Everolimus-eluting Stent for Coronary Atherosclerosis

Conditions:   Coronary Artery Disease;   Percutaneous Coronary Intervention;   Acute Coronary Syndrome;   Angina Pectoris
Intervention:   Device: Alpine
Sponsors:   Seoul National University Hospital;   Abbott
Recruiting - verified July 2016

Plasma Dipeptidyl-peptidase-4 Activities With No-reflow and Bleeding

Conditions:   Dipeptidyl-peptidase-4;   STEMI;   PCI;   No-reflow;   Bleeding
Intervention:  
Sponsor:   Chinese PLA General Hospital
Completed - verified July 2016

Evaluation of Soluble ST2 in Patients Receiving Primary PCI With ST-elevation Myocardial Infarction

Conditions:   Myocardial Infarction;   Shock
Intervention:  
Sponsor:   Wuhan Asia Heart Hospital
Recruiting - verified July 2016

The Northwest Coalition for Primary Care Practice Support

Conditions:   Cardiovascular Disease;   Essential Hypertension;   Nicotine Dependence;   Hyperlipidemia
Interventions:   Other: Coaching;   Other: Educational Outreach;   Other: Site Visits
Sponsors:   Group Health Cooperative;   University of Washington;   Oregon Health and Science University
Active, not recruiting - verified July 2016

" Endarterectomy Combined With Optimal Medical Therapy Versus Optimal Medical Therapy Alone in Patients With Asymptomatic Severe Atherosclerotic Carotid Artery Stenosis at Higher-than-average Risk of Ipsilateral Stroke "

Condition:   Asymptomatic Carotid Stenosis at Higher-than-average Risk of Ipsilateral Stroke
Interventions:   Other: Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT);   Drug: Optimal medical therapy alone
Sponsors:   Centre Hospitalier St Anne;   Hôpitaux Universitaires Paris Ile-de-Franc Ouest
Not yet recruiting - verified July 2016

Retrospective Study of Acute Chest Pain in Extremely Critical Condition for More Than Ten Years

Conditions:   Acute Myocardial Infarction;   Pulmonary Embolism;   Aortic Dissection
Intervention:  
Sponsor:   Qilu Hospital
Recruiting - verified July 2016

Ad-HGF Treatment for Myocardial Infarction

Condition:   Myocardial Infarction
Interventions:   Drug: Ad-HGF;   Other: 0.9% NaCl
Sponsor:   The First Affiliated Hospital with Nanjing Medical University
Not yet recruiting - verified June 2016

Intravascular Ultrasound Prediction of Myocardial Size and Coronary Computed Tomography-Derived Ischemic Burden for Coronary Lesion

Condition:   Coronary Artery Disease
Intervention:   Other: Intravascular Ultrasound, coronary computed tomography angiography
Sponsors:   Asan Medical Center;   Boston Scientific Corporation
Not yet recruiting - verified July 2016

Reactive Oxygen Species Following Aortic Valve Replacement

Condition:   Aortic Stenosis
Intervention:  
Sponsor:   University Hospital Southampton NHS Foundation Trust.
Recruiting - verified July 2016

TRANscatheter or SurgIcal Aortic Valve ReplacemenT in All-Comers With Severe Aortic Valve Stenosis

Condition:   Aortic Valve Stenosis
Interventions:   Device: SAPIEN 3;   Procedure: SAVR
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Not yet recruiting - verified July 2016

Efficacy of Aspirin and L-arginine in High Risk Preeclamptic

Condition:   High Risk Pregnancy
Interventions:   Drug: L-arginine;   Drug: Placebo (for L-arginine);   Drug: acetylsalicylic acid
Sponsors:   University of Guadalajara;   PhD Ernesto Javier Ramírez Lizardo;   PhD Sylvia Elena Totsuka Sutto;   PhD Fernando Grover Páez;   MD Diego Hernández Molina
Not yet recruiting - verified July 2016

Circulating PRCP in STEMI Patients Undergoing Primary PCI

Conditions:   Myocardial Infarction;   Percutaneous Coronary Intervention;   PRCP
Intervention:   Procedure: Primary PCI
Sponsor:   Qilu Hospital
Completed - verified July 2016

Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids

Condition:   Normal Physiology
Interventions:   Drug: Solu-Medrol (methylprednisolone sodium succinate);   Drug: Topical methylprenisolone 0.1%
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified July 2016

Plasma GLP1 and Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Conditions:   Coronary Angiography;   Glucagon-Like Peptide 1
Intervention:  
Sponsor:   Chinese PLA General Hospital
Recruiting - verified July 2016

A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction

Condition:   Acute Myocardial Infarction
Interventions:   Biological: CSL_112;   Other: Placebo
Sponsor:   CSL Behring
Not yet recruiting - verified July 2016

PARA-HEART Pilot Implementation

Conditions:   Acute Coronary Syndrome;   Chest Pain
Intervention:  
Sponsor:   Wake Forest Baptist Health
Not yet recruiting - verified July 2016

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified July 2016

Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications

Conditions:   Myocardial Ischemia;   Rheumatic Diseases
Intervention:   Other: Caplan IVR
Sponsor:   VA Office of Research and Development
Not yet recruiting - verified July 2016

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Conditions:   Anemia;   Non-dialysis-dependent Chronic Kidney Disease
Interventions:   Drug: vadadustat;   Drug: darbepoetin alfa
Sponsor:   Akebia Therapeutics
Recruiting - verified July 2016

Fractional Flow Reserve Versus Angiography for Guiding Selective Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction

Conditions:   Fractional Flow Reserve;   ST-segment Elevation Myocardial Infarction;   Percutaneous Coronary Intervention
Intervention:  
Sponsor:   Nanjing Medical University
Enrolling by invitation - verified January 2016

Fractional FLow Reserve And IVUS for Clinical OUtcomes in Patients With InteRmediate Stenosis

Condition:   Stable Angina
Intervention:   Device: Drug-eluting stent
Sponsors:   Seoul National University Hospital;   Ajou University School of Medicine;   Keimyung University Dongsan Medical Center;   Inje University
Recruiting - verified July 2016

Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"

Condition:   Thrombosis
Interventions:   Drug: BMS-986141;   Drug: Aspirin;   Other: Placebo
Sponsor:   Bristol-Myers Squibb
Recruiting - verified July 2016

Short-term Air Pollution Exposure and In-hospital Outcomes in Patients With Acute Myocardial Infraction

Conditions:   Air Pollution;   Acute Myocardial Infarction;   Percutaneous Coronary Intervention
Intervention:  
Sponsors:   Nanjing Medical University;   The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Enrolling by invitation - verified July 2016

Efficacy and Safety Study to Evaluate Vadadustat for the Correction of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Conditions:   Anemia;   Non-dialysis-dependent Chronic Kidney Disease
Interventions:   Drug: vadadustat;   Drug: darbepoetin alfa
Sponsor:   Akebia Therapeutics
Recruiting - verified July 2016

A Study of the ReCor Medical Paradise System in Clinical Hypertension

Conditions:   Hypertension;   Vascular Diseases
Interventions:   Device: The Paradise® Renal Denervation Ultrasound System;   Device: Sham Procedure
Sponsor:   ReCor Medical, Inc.
Recruiting - verified July 2016

Anti-inflammatory Effect of Therapeutic Hypothermia in Acute Myocardial Infarction Complicated With Cardiogenic Shock

Condition:   Cardiac Arrest
Intervention:   Device: Therapeutic hypothermia
Sponsor:   China Medical University Hospital
Recruiting - verified July 2016

Comparison of Loading Strategies With Antiplatelet Drugs in Patients Undergoing Elective Coronary Intervention

Condition:   Angina Pectoris
Interventions:   Drug: Prasugrel;   Drug: Clopidogrel
Sponsor:   Klinikum der Universitaet Muenchen
Recruiting - verified July 2016

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Condition:   Transcatheter Aortic Valve Replacement
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Acetylsalicylic acid;   Drug: Clopidogrel
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified July 2016

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified July 2016

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Condition:   Peripheral Artery Disease
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban-Placebo
Sponsors:   Bayer;   Janssen Research & Development, LLC;   Colorado Prevention Center
Recruiting - verified July 2016

Copeptin Registry (proCORE) Biomarkers in Cardiology (BIC)-19

Condition:   Acute Myocardial Infarction
Intervention:   Procedure: Routine management observation
Sponsor:   Charite University, Berlin, Germany
Recruiting - verified July 2016

Profile and Antithrombotic Management of Patients With NVAF Attending Internal Medicine Departments in Spain (PERFILAR Study)

Condition:   Anticoagulation, Blood Thinners , Atrial Fibrillation, Bleeding, Stroke
Intervention:  
Sponsor:   Bristol-Myers Squibb
Active, not recruiting - verified July 2016

CardiAMP™ Heart Failure Trial

Condition:   Heart Failure
Interventions:   Biological: Autologous cell therapy;   Device: CardiAMP cell therapy;   Other: Sham
Sponsor:   BioCardia, Inc.
Not yet recruiting - verified July 2016

A Multicenter Trial to Assess the MIcrovascular Integrity and Left Ventricular Function Recovery After Clopidogrel or TicagrelOr Administration, in Patients With STEMI Treated With Thrombolysis - The 'MIRTOS' Study

Conditions:   Myocardial Infarction;   ST Segment Elevation Myocardial Infarction (STEMI)
Interventions:   Drug: Ticagrelor;   Drug: Clopidogrel;   Procedure: Percutaneous Coronary Intervention (PCI);   Procedure: Coronary Angiography
Sponsor:   Hellenic Cardiovascular Research Society
Recruiting - verified July 2016

SONOlysis in Prevention of Brain InfaRctions During Internal Carotid Endarterectomy

Condition:   Internal Carotid Artery Stenosis
Intervention:   Device: sonolysis
Sponsors:   University Hospital Ostrava;   Military University Hospital, Prague;   Vitkovice Hospital, Ostrava;   Masaryk Hospital, Usti nad Labem;   České Budějovice Hospital;   University Hospital Hradec Kralove;   University Hospital Pilsen;   County Hospital Liberec, Liberec;   University Hospital, Martin;   Jihlava Hospital, Jihlava;   Na Homolce Hospital;   University Hospital, Motol;   Faculty Hospital Nitra;   University Hospital Olomouc;   University Hospital Kosice;   Bata Hospital, Zlin
Recruiting - verified April 2016

Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

Conditions:   Coronary Artery Disease;   Atherosclerosis, Coronary;   Myocardial Ischemia;   Ischemic Heart Disease;   Acute Coronary Syndrome;   Angina Pectoris
Interventions:   Device: Orsiro DES;   Device: Xience DES
Sponsors:   Biotronik, Inc.;   Biotronik AG;   Harvard Clinical Research Institute;   Medstar Research Institute
Active, not recruiting - verified July 2016

PCI With AXXESS Biolimus A9 Eluting Bifurcation Stent in Treating Coronary Artery Bifurcation Disease

Condition:   Coronary Bifurcation Lesions
Interventions:   Device: OCT-guided PCI with AXXESS stent;   Device: OCT-guided PCI with conventional DES (Biomatrix flex stent);   Device: Angio-guided PCI with AXXESS stent;   Device: Angio-guided PCI with PCI with conventional DES (Biomatrix flex stent)
Sponsor:   Yonsei University
Withdrawn - verified July 2016

Validation of Simple Acute Coronary Syndrome (SACS) Score

Conditions:   Chest Pain;   Acute Coronary Syndrome;   Angina;   Myocardial Infarction
Intervention:  
Sponsors:   Bayfront Health St Petersburg;   Bayfront Health Dade City;   Community Health Systems (CHS)
Enrolling by invitation - verified July 2016

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Conditions:   HIV Infections;   Cardiovascular Diseases
Interventions:   Drug: Pitavastatin;   Drug: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Heart, Lung, and Blood Institute (NHLBI);   Kowa Pharmaceuticals America, Inc.
Recruiting - verified July 2016

Weight Loss Referral for Healthier Survivorship in Obese Stage I-II Endometrial Cancer Survivors or Atypical Hyperplasia

Conditions:   Complex Endometrial Hyperplasia With Atypia;   Stage IA Uterine Corpus Cancer;   Stage IB Uterine Corpus Cancer;   Stage II Uterine Corpus Cancer
Interventions:   Behavioral: Weight Loss Specialist;   Other: Quality-of-Life Assessment;   Other: Medical Chart Review
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified July 2016

Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)

Condition:   Systemic Lupus Erthematosus
Interventions:   Radiation: PET/CT;   Drug: Pioglitazone;   Procedure: Vascular function studies
Sponsor:   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified July 2016

Timing of Coronary Angiography, Cardiac Surgery, and Adverse Renal and Cardiac Events (MARCE)

Conditions:   Acute Kidney Injury;   Renal Insufficiency
Intervention:   Procedure: cardiac surgery
Sponsor:   Baylor Research Institute
Active, not recruiting - verified July 2016

China PEACE II: Quality Improvement for Acute Myocardial Infarction

Condition:   Acute Myocardial Infarction
Interventions:   Behavioral: Quality improvement strategies and tools;   Behavioral: Process optimization
Sponsor:   China National Center for Cardiovascular Diseases
Active, not recruiting - verified July 2016

A Study of VentriGel in Early and Late Post-myocardial Infarction Patients

Conditions:   Myocardial Infarction;   Heart Failure;   Left Ventricular Remodeling
Intervention:   Biological: VentriGel
Sponsor:   Ventrix, Inc.
Enrolling by invitation - verified July 2016

Combined Coronary and Cerebral Angiography and Intervention for Coronary and Cerebrovascular Atherosclerosis

Conditions:   Coronary Stenosis;   Cerebral Stenosis
Interventions:   Other: simultaneous coronary and cerebral intervention;   Other: staged coronary and cerebral intervention
Sponsor:   Capital Medical University
Recruiting - verified July 2016

REPRISE Next Generation Delivery System

Condition:   Aortic Stenosis
Intervention:   Device: Lotus Valve and LOTUS Edge Valve System
Sponsor:   Boston Scientific Corporation
Recruiting - verified July 2016

Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry

Condition:   Acute Coronary Syndromes
Intervention:   Other: Non-Interventional Study
Sponsor:   AstraZeneca
Recruiting - verified July 2016

Berlin Atrial Fibrillation Registry

Conditions:   Acute Ischemic Stroke;   Atrial Fibrillation
Intervention:  
Sponsors:   Charite University, Berlin, Germany;   Center for Stroke Research Berlin;   Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Recruiting - verified July 2016

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Conditions:   Stroke;   Secondary Prevention
Interventions:   Drug: optional ASA as comedication;   Drug: placebo to ASA;   Drug: placebo to optional ASA as comedication;   Drug: placebo to dabigatran etexilate;   Drug: ASA 100 mg;   Drug: dabigatran etexilate
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2016

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Epoetin alfa
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified July 2016

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Placebo
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified July 2016

Diuretic Comparison Project

Condition:   Hypertension
Interventions:   Drug: Hydrochlorothiazide (HCTZ);   Drug: Chlorthalidone
Sponsor:   VA Office of Research and Development
Recruiting - verified July 2016

The Safety of High Dose Minocycline in the Patient Population Undergoing Carotid Revascularization

Condition:   Stroke
Intervention:   Drug: Administration of minocycline
Sponsor:   University of Pittsburgh
Terminated - verified July 2016

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: Dabigatran Etexilate 110mg;   Drug: Warfarin 3mg;   Drug: Aspirin;   Drug: Dabigatran Etexilate 150mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 5mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 1mg
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2016

3D Multi-Contrast Atherosclerosis Characterization of the Carotid Artery

Condition:   Carotid Artery Disease
Intervention:   Other: MRI with/without contrast
Sponsors:   Cedars-Sinai Medical Center;   National Heart, Lung, and Blood Institute (NHLBI);   American Heart Association
Recruiting - verified July 2016

ASV for Sleep Apnea After Myocardial Infarction

Conditions:   Acute Myocardial Infarction;   Sleep Apnea
Intervention:   Device: Adaptive servo-ventilation
Sponsors:   University Hospital Regensburg;   ResMed Foundation
Recruiting - verified July 2016

Detection and Significance of Heart Injury in ST Elevation Myocardial Infarction.

Condition:   Acute ST-elevation Myocardial Infarction
Interventions:   Device: Coronary pressure wire;   Other: Magnetic resonance imaging of the heart
Sponsors:   NHS National Waiting Times Centre Board;   Siemens Healthcare Diagnostics Inc;   British Heart Foundation
Active, not recruiting - verified July 2016

Revascularisation or Medical Therapy in Elderly Patients With Acute Anginal Syndromes

Condition:   Acute Coronary Syndromes
Interventions:   Drug: Conservative Arm;   Procedure: Invasive Arm
Sponsors:   Brighton and Sussex University Hospitals NHS Trust;   Medtronic Vascular
Recruiting - verified July 2016

Study of Effects of Ticagrelor on Microparticles and Micro-RNA in NSTE-ACS

Condition:   Non ST Segment Elevation Acute Coronary Syndrome
Interventions:   Drug: Ticagrelor;   Drug: Clopidogrel
Sponsor:   Catholic University of the Sacred Heart
Terminated - verified July 2016

IRIS-PREMIER REGISTRY

Conditions:   Coronary Artery Disease;   Myocardial Ischemia;   Coronary Disease;   Heart Diseases
Intervention:   Device: Promus PREMIER
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea;   Boston Scientific Korea Co. Ltd
Active, not recruiting - verified July 2016

Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis

Condition:   Saphenous Vein Graft Disease
Interventions:   Drug: Aspirin;   Drug: Ticagrelor
Sponsors:   Boca Raton Regional Hospital;   AstraZeneca;   Ottawa Heart Institute Research Corporation
Recruiting - verified July 2016

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

Condition:   Atrial Fibrillation
Interventions:   Drug: Apixaban;   Drug: Parenteral heparin and/or oral Vitamin K antagonist
Sponsors:   Pfizer;   Bristol-Myers Squibb
Recruiting - verified July 2016

Verification of the Safety of Early Discharge in Patients After Acute ST-segment Myocardial Infarction

Conditions:   Coronary Artery Disease;   Acute Myocardial Infarction With ST-segment Elevation;   Primary Percutaneous Coronary Intervention;   Early Discharge
Interventions:   Other: Early discharge;   Other: Standard discharge
Sponsor:   Kamil Novobílský
Recruiting - verified July 2016

Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation

Conditions:   Ischemic Stroke;   Transient Ischemic Attack
Interventions:   Drug: Rivaroxaban;   Drug: Warfarin
Sponsors:   Asan Medical Center;   Bayer
Completed - verified July 2016

STem cElls Mobilization in Acute Myocardial Infarction Outcome Trial

Conditions:   Anterior Acute Myocardial Infarction;   Left Ventricular Systolic Dysfunction
Intervention:   Drug: G-CSF administration
Sponsors:   Heart Care Foundation;   A. Manzoni Hospital;   Centro Cardiologico Monzino
Suspended - verified March 2015

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Active, not recruiting - verified July 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Sponsor:   Bayer
Recruiting - verified July 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified July 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified July 2016

Study of Efficacy and Safety of Percutaneous Coronary Intervention to Improve Survival in Heart Failure

Condition:   Ischemic Cardiomyopathy
Interventions:   Procedure: Percutaneous Coronary Intervention;   Drug: Drug Therapy for Heart Failure;   Device: Device Therapy for Heart Failure
Sponsors:   King's College London;   National Institute for Health Research, United Kingdom;   London School of Hygiene and Tropical Medicine (Clinical Trials Unit);   University of York;   Guy's and St Thomas' NHS Foundation Trust
Recruiting - verified July 2016

ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial

Condition:   Peripheral Endovascular Interventions
Intervention:   Drug: Bivalirudin
Sponsor:   The Medicines Company
Active, not recruiting - verified July 2016

ROOBY Trial Follow-up Extension

Conditions:   All Cause Mortality;   MACE
Intervention:  
Sponsor:   VA Office of Research and Development
Active, not recruiting - verified July 2016

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2016

Conservative Non-Invasive Versus Routine Invasive Management in Coronary Artery Bypass Surgery Patients With Non ST Elevation Elevation Acute Coronary Syndrome

Conditions:   Non ST Elevation Myocardial Infarction;   Unstable Angina
Intervention:   Procedure: Invasive management
Sponsors:   NHS National Waiting Times Centre Board;   University of Glasgow
Completed - verified July 2016

Study Of Diabetic Nephropathy With Atrasentan

Condition:   Diabetic Nephropathy
Interventions:   Drug: Atrasentan;   Drug: Placebo
Sponsor:   AbbVie
Recruiting - verified July 2016

ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial

Condition:   End Stage Renal Failure on Dialysis
Interventions:   Drug: Spironolactone;   Drug: Placebo
Sponsors:   University Hospital, Brest;   Central Hospital, Nancy, France;   Institut National de la Santé Et de la Recherche Médicale, France
Recruiting - verified July 2016

Revascularization Strategies for STEMI; The CMR Endpoint Study

Condition:   Acute Myocardial Infarction
Interventions:   Procedure: IRA-PCI;   Procedure: SS-PCI
Sponsor:   St. Michael's Hospital, Toronto
Recruiting - verified July 2016

Identify Clinical Conditions That Increase Circulating DNA Levels

Conditions:   Pregnancy;   Pulmonary Embolism;   Myocardial Infarction;   Autoimmune Disease
Intervention:   Other: One time blood draw to look at patient's DNA
Sponsor:   University of Florida
Active, not recruiting - verified July 2016

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Condition:   Prevention &Amp; Control
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin;   Drug: Aspirin placebo;   Drug: Rivaroxaban placebo;   Drug: Pantoprazole
Sponsors:   Bayer;   Hamilton Health Sciences Corporation, Population Health Research Institute
Recruiting - verified July 2016

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Condition:   Dyslipidemia
Interventions:   Biological: Evolocumab (AMG 145);   Other: Placebo;   Drug: Effective statin therapy
Sponsor:   Amgen
Active, not recruiting - verified July 2016

Fractional Flow Reserve Versus Angiographically Guided Management to Optimise Outcomes in Unstable Coronary Syndromes

Conditions:   Non-ST Elevation Myocardial Infarction.;   Type 1 Myocardial Infarction.
Intervention:   Device: Fractional flow reserve
Sponsors:   NHS National Waiting Times Centre Board;   British Heart Foundation;   St. Jude Medical;   University of Glasgow
Active, not recruiting - verified July 2016

Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty

Condition:   Venous Thromboembolism
Intervention:   Drug: rivaroxaban and ASA
Sponsors:   David Anderson;   Canadian Institutes of Health Research (CIHR)
Active, not recruiting - verified July 2016

Anti-inflammatory Effects of Colchicine in PCI

Condition:   Coronary Artery Disease
Interventions:   Drug: Colchicine;   Drug: Placebo
Sponsors:   New York University School of Medicine;   Takeda
Recruiting - verified July 2016

A Study of Evacetrapib in High-Risk Vascular Disease

Condition:   Cardiovascular Diseases
Interventions:   Drug: Evacetrapib;   Drug: Placebo
Sponsors:   Eli Lilly and Company;   The Cleveland Clinic
Active, not recruiting - verified July 2016

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2016

A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta

Condition:   Acute Coronary Syndromes
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified July 2016

The Supplementary Role of Non-invasive Imaging to Routine Clinical Practice in Suspected Non-ST-elevation Myocardial Infarction

Conditions:   Chest Pain;   Myocardial Infarction;   Acute Coronary Syndrome;   Coronary Artery Disease;   Myocardial Ischemia
Interventions:   Other: Cardiovascular Magnetic Resonance Imaging;   Other: Computed Tomography Angiography
Sponsors:   Maastricht University Medical Center;   Dutch Heart Foundation
Active, not recruiting - verified July 2016

Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)

Condition:   Saphenous Vein Graft Disease
Interventions:   Drug: Atorvastatin 80 mg daily;   Drug: Atorvastatin 10 mg daily
Sponsors:   Boca Raton Regional Hospital;   Pfizer
Active, not recruiting - verified July 2016

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2016

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Condition:   Crohn's Disease
Interventions:   Drug: CP-690,550;   Drug: CP-690,550
Sponsor:   Pfizer
Recruiting - verified July 2016

Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

Condition:   Leukemia
Interventions:   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Ponatinib;   Drug: G-CSF (Filgrastim);   Drug: Rituximab;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Solu-medrol ( Methyl Prednisolone);   Drug: Citrovorum (Leucovorin);   Drug: Prednisone;   Drug: Pegfilgrastim (Neulasta)
Sponsors:   M.D. Anderson Cancer Center;   Ariad Pharmaceuticals
Active, not recruiting - verified July 2016

PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)

Condition:   Non-ischemic Dilated Cardiomyopathy
Interventions:   Procedure: Transendocardial injection;   Biological: Autologous hMSCs;   Biological: Allogeneic hMSCs
Sponsors:   Joshua M Hare;   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting - verified July 2016

Identification of Genomic Predictors of Adverse Events After Cardiac Surgery

Conditions:   Heart; Dysfunction Postoperative, Cardiac Surgery;   Genetic Predisposition to Disease;   Atrial Fibrillation;   Myocardial Infarction;   Heart Failure
Intervention:  
Sponsors:   Brigham and Women's Hospital;   National Heart, Lung, and Blood Institute (NHLBI);   Texas Heart Institute;   University of Texas Southwestern Medical Center
Recruiting - verified July 2016

Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)

Condition:   Ankylosing Spondylitis
Intervention:  
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified July 2016

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus Type 2
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2016

IK-1001 (Sodium Sulfide (Na2S) for Injection) in Subjects With Acute ST-Segment Elevation Myocardial Infarction

Condition:   ST-Segment Elevation Myocardial Infraction
Interventions:   Drug: Sodium Sulfide (Na2S) for Injection;   Drug: Placebo
Sponsor:   Mallinckrodt
Withdrawn - verified July 2016

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Condition:   Ischemic Attack, Transient
Interventions:   Drug: Clopidogrel;   Drug: placebo
Sponsors:   University of California, San Francisco;   Neurological Emergencies Treatment Trials Network (NETT);   Medical University of South Carolina;   The EMMES Corporation
Recruiting - verified July 2016

Erythropoietin in Traumatic Brain Injury (EPO-TBI)

Condition:   Traumatic Brain Injury
Interventions:   Drug: Epoetin Alfa;   Drug: Sodium Chloride 0.9%
Sponsors:   Australian and New Zealand Intensive Care Research Centre;   National Health and Medical Research Council, Australia;   Australian and New Zealand Intensive Care Society Clinical Trials Group;   Monash University
Completed - verified July 2016

Associations Between Diabetes Care and Haptoglobin Genotype On outComes

Conditions:   Diabetes;   Cardiovascular Disease;   Myocardial Infarction;   Stroke
Intervention:  
Sponsor:   Clalit Health Services
Active, not recruiting - verified July 2016

Cardiac FDG PET Viability Registry

Conditions:   Heart Failure;   Ischemic Heart Disease;   Myocardial Dysfunction
Intervention:  
Sponsors:   Ottawa Heart Institute Research Corporation;   Ontario Ministry of Health and Long Term Care
Recruiting - verified July 2016

Natural Killer Cells and Bortezomib to Treat Cancer

Conditions:   Lung or Prostatic Neoplasms;   Colorectal or Kidney Neoplasms;   Pancreatic Neoplasms;   Leukemia, Myelogenous, Chronic Lymphocytic Leukemia, BCR-ABL Positive;   Melanoma;   CLL
Intervention:   Drug: NK cells +CliniMACs CD3 and CD56 systems
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2016

The Melatonin Adjunct in the Acute myocaRdial Infarction Treated With Angioplasty

Condition:   Acute Myocardial Infarction
Intervention:   Drug: melatonin
Sponsor:   Alberto Domínguez Rodríguez
Terminated - verified July 2016

Abrupt Versus Tapered Interruption of Chronic Clopidogrel Therapy After DES Implantation

Condition:   Coronary Artery Disease
Interventions:   Drug: Abrupt Clopidogrel Interruption;   Drug: Clopidogrel Tapering
Sponsor:   Deutsches Herzzentrum Muenchen
Terminated - verified June 2012

Using Differences in Peripheral Blood Leukocyte Gene Expression to Determine Cardiovascular Disease Risk

Conditions:   Atherosclerosis;   Cardiovascular Diseases
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified April 2009

Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome

Condition:   Antiphospholipid Syndrome
Intervention:  
Sponsor:   Duke University
Recruiting - verified July 2016

PET and Recovery Following Revascularization (PARR 2)

Conditions:   Coronary Artery Disease;   Ventricular Dysfunction, Left
Interventions:   Procedure: Positron emission tomography: FDG viability imaging;   Other: PET imaging
Sponsors:   Ottawa Heart Institute Research Corporation;   Canadian Institutes of Health Research (CIHR);   Heart and Stroke Foundation of Ontario
Completed - verified July 2016

Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen

Condition:   Arthritis, Rheumatoid
Interventions:   Drug: celecoxib;   Drug: Ibuprofen;   Drug: Naproxen
Sponsors:   Pfizer;   The Cleveland Clinic
Completed - verified July 2016

Heavy Metals, Obesity and Cardiovascular Risk - Ancillary to Look AHEAD

Conditions:   Diabetes Mellitus, Non-insulin Dependent;   Cardiovascular Diseases;   Obesity;   Myocardial Infarction;   Heart Diseases;   Diabetes Mellitus
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified January 2008

MRI Derived Organ & Tissue Mass Changes With Weight Loss - Ancillary to Look AHEAD

Conditions:   Cardiovascular Diseases;   Atherosclerosis;   Obesity;   Diabetes Mellitus, Non-insulin Dependent;   Heart Diseases;   Myocardial Infarction;   Diabetes Mellitus
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified January 2008

Worcester Heart Attack Community Surveillance Study

Conditions:   Cardiovascular Diseases;   Heart Diseases;   Coronary Disease;   Myocardial Infarction
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified May 2009

Multi-Ethnic Study of Atherosclerosis (MESA)

Conditions:   Atherosclerosis;   Cardiovascular Diseases;   Heart Diseases;   Coronary Artery Disease;   Coronary Disease;   Stroke;   Myocardial Infarction;   Heart Failure;   Diabetes Mellitus, Type 2;   Hypertension;   Diabetes Mellitus
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting - verified April 2012

Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Diabetes Mellitus;   Heart Diseases;   Hypercholesterolemia;   Hypertension;   Myocardial Infarction;   Myocardial Ischemia;   Heart Failure
Interventions:   Drug: Inhibitors, ACE;   Drug: amlodipine;   Drug: lisinopril;   Drug: doxazosin;   Drug: chlorthalidone;   Drug: pravastatin;   Behavioral: diet, fat-restricted
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2009